Cutaneous T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Cutaneous T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas [Phase 2]
Phase 2 clinical trial update evaluating pembrolizumab with mogamulizumab in advanced-stage, relapsed/refractory cutaneous T-cell lymphoma, …
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL [Phase 1]
Phase 1 study of CAR-T cells targeting CD30 and CCR4 for relapsed/refractory CD30+ Hodgkin lymphoma and cutaneous T-cell lymphoma, with the …
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
This clinical trial update indicates ongoing recruitment for a University of Pittsburgh study collecting blood, urine, and tissue samples fr…
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
A real-world study reports on the use of mogamulizumab for treating cutaneous T-cell lymphoma and its subtypes.
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Amping up With PemJAK [Phase 2]
A Phase 2 clinical trial of PemJAK for multiple lymphoma subtypes is currently recruiting, including non-Hodgkin lymphoma and Hodgkin lympho…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
A clinical trial update notes ongoing recruitment for systemic therapies in the treatment of cutaneous T-cell lymphoma, including mycosis fu…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas [Phase 2]
Clinical trial update indicates a Phase 2 study of the JAK1 inhibitor golidocitnib for relapsed/refractory indolent T- and NK-cell lymphomas…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Tissue Repository: CTCL Collection Protocol
This clinical trial update describes a tissue repository protocol for collecting samples related to cutaneous T-cell lymphoma (CTCL) and rel…
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma [Phase 2]
Phase 2 trial evaluating the combination of extracorporeal photopheresis and mogamulizumab for erythrodermic cutaneous T-cell lymphoma, curr…
-
CLINICAL_TRIALS trial_result · 2025-10-09Clinical Trial Update: A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) [EARLY_Phase 1]
A first-in-human Phase 1 dose-escalation study of DT-7012, a CCR8-targeting monoclonal antibody from Domain Therapeutics, in relapsed or ref…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: StrataCTX® as a Steroid Sparing Device [NA]
This clinical trial update reports that StrataCTX is being studied as a steroid-sparing device for cutaneous T-cell lymphoma and that the tr…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Photopheresis in Early-stage Mycosis Fungoides [Phase 2]
Phase 2 trial evaluating photopheresis in early-stage mycosis fungoides (cutaneous T cell lymphoma) is currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of ST-001 nanoFenretinide for relapsed/refractory T-cell non-Hodgkin lymphoma is currently recruiting, targeting multiple T-ce…
-
CLINICAL_TRIALS trial_result · 2025-09-19Clinical Trial Update: Romidepsin Maintenance After Allogeneic Stem Cell Transplantation [Phase 1]
Phase 1 trial update on romidepsin as maintenance therapy after allogeneic stem cell transplantation. The study status is completed and incl…
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance [Phase 3]
Phase 3 trial evaluating Brentuximab Vedotin as maintenance therapy after allogeneic hematopoietic stem cell transplant in cutaneous T-cell …
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: Local Registry of Primary Cutaneous T-cell Lymphomas
A local registry study for Primary cutaneous T-cell lymphoma is currently recruiting at Fondazione IRCCS Policlinico San Matteo di Pavia.
-
CLINICAL_TRIALS trial_result · 2025-08-27Clinical Trial Update: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma [Phase 4]
Phase 4 trial evaluating Brentuximab Vedotin in Chinese adults with CD30-positive cutaneous T-cell lymphoma has completed with results poste…
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL [Phase 2]
Phase 2 trial comparing HyBryte (synthetic hypericin) to Valchlor (mechlorethamine gel) for Cutaneous T-Cell Lymphoma/Mycosis Fungoides has …
-
EMA approval · 2025-08-12EMA Authorised: Targretin (bexarotene) — H.A.C. Pharma
The European Medicines Agency authorised Targretin (bexarotene) for cutaneous T-cell lymphoma, with H.A.C. Pharma as the marketing authoriza…
-
CLINICAL_TRIALS trial_result · 2025-07-25Clinical Trial Update: Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma [Phase 2]
A Phase 2 study evaluating brentuximab vedotin in combination with lenalidomide for stage IB-IVB relapsed or refractory T-cell lymphoma has …
-
CLINICAL_TRIALS trial_result · 2025-07-18Clinical Trial Update: Ritlecitinib in CTCL [Phase 2]
A Phase 2 trial of ritlecitinib for cutaneous T-cell lymphoma was terminated.
-
CLINICAL_TRIALS research · 2025-07-15Clinical Trial Update: Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of duvelisib and venetoclax in relapsed or refractory peripheral T-cell lymphoma, w…
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System [Phase 1]
Phase 1 trial investigating safety and activity of a novel TNFR2 inhibitor in adults with non-Hodgkin lymphoma, including cutaneous T-cell l…
-
CLINICAL_TRIALS research · 2025-07-04Clinical Trial Update: Long-term Assessment of Chlormethine Gel in Mycosis Fungoides
This clinical trial update outlines a long-term assessment of chlormethine gel (mechlorethamine) for treating mycosis fungoides, a form of c…
-
CLINICAL_TRIALS withdrawal · 2025-06-27Clinical Trial Update: BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating cemiplimab for advanced cutaneous T-cell lymphoma (Mycosis fungoides) has been withdrawn (NCT05538988)…